# Alisertib for Acute Myeloid Leukemia

> **NCT01779843** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 22 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT01779843
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01779843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01779843, "Alisertib for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01779843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*